Search

Your search keyword '"Petta, S."' showing total 1,303 results

Search Constraints

Start Over You searched for: Author "Petta, S." Remove constraint Author: "Petta, S."
1,303 results on '"Petta, S."'

Search Results

1. T.07.2: LONG-TERM THERAPY WITH INTRAVENOUS HUMAN ALBUMIN INCREASE SURVIVAL IN PATIENTS WITH DECOMPENSATED CIRRHOSIS AND REFRACTORY ASCITES

3. OC.05.2: FIRST AND FURTHER LIVER DECOMPENSATION IN PATIENTS WITH METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE: WHAT CLINICAL IMPACT?

4. A global research priority agenda to advance public health responses to fatty liver disease

5. Corrigendum to: “Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆” [J Hepatol (2020) 505–515, (S0168827820302130), (10.1016/j.jhep.2020.04.003)]

6. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

7. Global multi-stakeholder endorsement of the MAFLD definition

8. Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic Hepatitis C aged 75 years or older: A multicenter study

9. SIRT5 rs12216101 T>G variant is associated with oxidative stress and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease

10. Hepatocyte depletion of ERK5 impairs the response to lipotoxic oxidative stress resulting in defective insulin receptor signaling

11. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced nonalcoholic fatty liver disease

12. T.11.6 TREATMENT WITH GLECAPREVIR AND PIBRENTASVIR IS SAFE AND EFFECTIVE IN ITALIAN

13. Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease

14. OC.08.1 PROGRAMMED CELL DEATH 1 GENETIC VARIANT AND LIVER DAMAGE IN NONALCOHOLIC FATTY LIVER DISEASE

15. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease and type 2 diabetes

17. A multi-society Delphi consensus statement on new fatty liver disease nomenclature

18. Corrigendum to 'Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)' Nutrition, Metabolism and Cardiovascular diseases volume 32 issue 1 (2022) 1-16

19. Corrigendum to 'Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)' [Dig Liver Dis 54 (2022) 170-182]

21. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study

22. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD : an individual patient data meta-analysis

23. Heart rate variability is associated with disease severity and portal hypertension in cirrhosis

24. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

25. Italian association for the study of the liver position statement on SARS-CoV2 vaccination

26. Corrigendum to: “Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort”☆ (J Hepatol [2020] 505–515) (Journal of Hepatology (2020) 73(3) (505–515), (S0168827820302130), (10.1016/j.jhep.2020.04.003))

29. Outcomes of Liver Transplant for Adults With Wilson’s Disease

30. Machine Perfusions in Liver Transplantation: The Evidence-Based Position Paper of the Italian Society of Organ and Tissue Transplantation

31. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆

32. Optimization of hepatitis C virus screening strategies by birth cohort in Italy

33. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

34. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?

37. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

39. Efficacy and safety of pangenotypic DAAs for chronic HCV infection: real-world data from the RESIST-HCV cohort

41. Increased burden of inherited IRF3 rare genetic variants in Europeans with severe NAFLD

43. Digestive diseases. 2022-2025 edition

44. Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease

45. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?

46. Advancing the global public health agenda for NAFLD: a consensus statement

47. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis

48. THE ROLE OF TRANSIENT ELASTOGRAPHY IN NAFLD

50. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

Catalog

Books, media, physical & digital resources